Orthogen AG

The ORTHOGEN AG Company is a biopharmaceutical company group, which operates in the field of molecular orthopaedics for 12 years. They are specialized – in close collaboration with leading universities like Harvard and Pittsburgh – in the development of therapeutical biologicals. In 1995 the company in Düsseldorf developed the worldwide first gene therapy for rheumatoid arthritis, in 1997 followed the development of the body’s own therapy for osteoarthritis called Orthokine. And in July 2004 the first clinical study about efficacy and safety of Orthokine in the treatment of nerve root inflammation was positively completed. “Our strength is the good scientific network and the early clinical use“, says the founder and CEO Prof. Dr. med. Peter Wehling. Right now there are 25 employees based in Düsseldorf.